PT  - JOURNAL ARTICLE
AU  - Dressel, Alexander
AU  - Hannich, Malte Johannes
AU  - Süße, Marie
TI  - Prospective multicenter validation of a new laboratory workflow integrating the free light chains kappa quotient in CSF analysis-Protocol of the ORCAS study
AID  - 10.1101/2023.07.16.23292727
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.16.23292727
4099  - http://medrxiv.org/content/early/2023/07/17/2023.07.16.23292727.short
4100  - http://medrxiv.org/content/early/2023/07/17/2023.07.16.23292727.full
AB  - Introduction Free light chain kappa (FLCκ) are a newer sensitive biomarker to detect intrathecal immunoglobulin synthesis. Here we report the study protocol of the ORCAS study which will evaluate a novel laboratory work flow recently proposed including FLCκ analysis simplifying cerebrospinal fluid (CSF) analysis.Methods The ORCAS study is a prospective multicenter diagnostic biomarker study across at least 4 study sites. The study protocol does not specify which assays should be applied in the participating laboratories to detect oligoclonal bands (OCB) or measure FLCκ or Ig synthesis to represent real world data. Primary outcome parameter is the sensitivity and negative predictive value of the absence of local FLCκ synthesis for the absence of intrathecal synthesis according to OCB and/or intrathecal IgG, IgA, IgM synthesis in quotient diagrams. The reference range of FLCκ will be indicated by the FLCκ quotient diagram. This study was designed according to the STARD criteria.Perspective The establishment of a newer biomarker in routine practice is associated with significant difficulties, such as the inconsistent comparability of different measurement platforms, the establishment of suitable cut-offs or insufficient knowledge regarding sensitivity and specificity of the biomarker. If the ORCAS study objective is achieved, the use of the proposed workflow integrating FLCκ analysis in routine practice in CSF diagnostics could help to better characterize the intraindividual and disease-specific intrathecal humoral immune response in a resource-efficient manner.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Universitymedicine Greifswald gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCNScentral nervous systemCSFCerebrospinal fluidFLCκFree light chains kappaGFRglomerular filtration rateIFintrathecal fractionIgImmunoglobulinOCBOligoclonal bandsQAlbAlbumin quotientQlimupper limit of the reference range